Lyell Immunopharma, Inc. — Director's Dealing 2021

Jun 17, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-16

Reporting Person: Turner Heather D (Chief General Counsel)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$3.65	2029-04-22	Common Stock (500000)		Direct
Option (right to buy)	$3.65	2030-01-15	Common Stock (165000)		Direct
Option (right to buy)	$5.96	2030-11-16	Common Stock (550000)		Direct

Footnotes

F1: 1/4 of the option shares vested on April 1, 2020, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.

F2: The shares vest in equal monthly installments over the forty-eight months following February 1, 2020.

F3: The shares vest in equal monthly installments over the forty-eight months following December 1, 2020.